PRINCETON, N.J., July 12 /PRNewswire/ — Novo Nordisk Inc.,
a global healthcare company and leader in diabetes care, today
announced the second issue of the Novo Nordisk BlueSheet, a
resource for information on diabetes and chronic disease,
highlighting key issues in diabetes prevention, detection,
treatment and care.
The second issue of the Novo Nordisk BlueSheet examines how
insulin has evolved over the last 90 years, how it is developed
today, the use of insulin devices in the U.S., and the outlook for
next generation insulins. Each quarter, the Novo Nordisk BlueSheet
will highlight key issues in diabetes prevention, detection,
treatment and care, as well as related topics from the legislative
process to public education.
To read the Novo Nordisk BlueSheet, go to: http://press.novonordisk-us.com/bluesheet.
“Innovation and scientific research and discovery are our most
powerful tools in defeating diabetes with better methods of disease
prevention, detection, treatment, and care,” said Jerzy Gruhn, president of Novo Nordisk
Inc. “At Novo Nordisk, we are committed to building an environment
that supports the discovery of new products and solutions that can
significantly impact the millions of people living with
diabetes.”
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 87
years of innovation and leadership in diabetes care. The
company also has leading positions within hemophilia care, growth
hormone therapy and hormone th
‘/>”/>
